New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 29, 2013
12:55 EDTPFEEarnings Preview: Pfizer shares up about 12% since reporting Q4 results
Pfizer (PFE) is scheduled to report Q1 earnings before the open on Tuesday, April 30, with a conference call scheduled for 10:00 am ET. Pfizer develops and produces medicines and vaccines for a wide range of conditions including in the areas of immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain. EXPECTATIONS: Analysts are looking for EPS of 56c on revenue of $14.0B, according to First Call. The consensus range for EPS is 52c-63c on revenue of $13.06B-$14.37B. LAST QUARTER: Pfizer reported Q4 EPS of 47c against estimates of 44c on revenue of $15.1B against estimates of $14.37B. Pfizer cited Lipitor's loss of exclusivity in most major markets as a negative in Q4. At the time of its Q4 earnings release, the drug giant gave FY13 EPS guidance of $2.20-$2.30 on a consensus of $2.29. STREET RESEARCH: On March 18, Wells Fargo called Pfizer its top large cap pick in Pharma. PRICE ACTION: Pfizer shares are up approximately 12% since reporting Q4 results on January 29.
News For PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 4, 2015
06:44 EDTPFEPfizer price target raised to $51 from $48 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss raised his price target for Pfizer (PFE) to $51 following yesterday's closure of the company's Hospira (HSP) acquisition. Purkiss now sees Pfizer's 2015-2019 adjusted earnings annual growth rate at 13%, versus the consensus at 9%. He sees a "compelling entry point" following the recent pullback and calls Pfizer his top pick in the U.S. Pharma group.
September 3, 2015
09:01 EDTPFEPfizer completes acquisition of Hospira
Subscribe for More Information
September 1, 2015
18:19 EDTPFEJudge says inclined to proceed with Pfizer lawsuit, WSJ reports
Subscribe for More Information
August 31, 2015
09:11 EDTPFEEuropean Society of Cardiology
Subscribe for More Information
August 27, 2015
17:38 EDTPFES&P announces changes to S&P 500 index
Subscribe for More Information
07:24 EDTPFEPfizer shares even more compelling after recent weakness, says Piper Jaffray
Subscribe for More Information
06:55 EDTPFEHospira sees merger closing on or about September 3
Hospira (HSP) said in a regulatory filing that on August 21, Hospira and Pfizer (PFE) received clearance from the U.S. FTC, relating to the pending merger of Hospira with Perkins Holding Company, a wholly-owned subsidiary of Pfizer. All required regulatory approvals have now been secured, though the merger remains conditioned upon the expiration of a post-clearance waiting period in one foreign jurisdiction. Hospira expects the merger to close on or about September 3.
August 26, 2015
07:32 EDTPFEPfizer launches Phase 3 trial of targeted therapy for breast cancer patients
Subscribe for More Information
06:16 EDTPFEAlvogen to acquire product portfolio from Pfizer for US market
Subscribe for More Information
August 25, 2015
14:16 EDTPFEMylan launches generic version of Pfizer's Zosyn Injection
Mylan (MYL) announced the U.S. launch of Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials, which is the generic version of Pfizer's (PFE) Zosyn Injection. This product is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated for the treatment of patients with moderate to severe infections caused by susceptible isolates of certain bacteria. Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials had U.S. sales of approximately $72.1M for the 12 months ending June 30, 2015, according to IMS Health. Mylan's launch of this product adds to the company's growing portfolio of more than 145 injectable products available to patients in the U.S. across a broad array of therapeutic categories including oncology, anti-infectives, anesthesia/pain management and cardiovascular.
August 24, 2015
12:57 EDTPFEFTC requires Pfizer to sell rights to four products as condition of buying Hospira
Subscribe for More Information
08:16 EDTPFEBristol-Myers, Pfizer to present new data on Eliquis at ESC Congress 2015
Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) announced that 22 abstracts will be presented at the ESC Congress 2015, to be held August 29 to September 2 in London, United Kingdom. The new data reinforce the Alliance's commitment to the ongoing evaluation of Eliquis in both the nonvalvular atrial fibrillation and venous thromboembolism patient populations. In addition, data from the AEGEAN study evaluating adherence among NVAF patients further extends the Alliance's commitment to patient care.
08:01 EDTPFEPfizer receives clearance from FTC for Hospira acquisition
Subscribe for More Information
August 23, 2015
12:35 EDTPFEBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use